IP Library › Granted Patent US 9,402,827
Granted Patent B2
US 9,402,827 · App. 13/637,343 · Granted Aug 2, 2016

Treatment of gout

Inventors: Jeffrey Miner (San Diego, CA); Jean-Luc Girardet (San Diego, CA); Barry D. Quart (Encinitas, CA)
Assignee: ARDEA BIOSCIENCES, INC.
A61K31/41A61K31/165A61K31/4196
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,402,827
App. No.
13/637,343
Granted
Aug 2, 2016
Kind
B2
Abstract

Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses such compositions for the treatment of a variety of diseases and conditions.

Claims (14)

1. A method of treating gout comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, and colchicine to a subject, wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 400 mg or about 200 mg, and the dosage of colchicine is 0.3 mg to 1.2 mg.

2. The method of claim 1 , wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 400 mg.

3. The method of claim 1 , wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 200 mg.

4. The method of claim 2 , wherein the daily dose is administered orally.

5. The method of claim 2 , wherein the daily dose is administered in the morning.

6. The method of claim 2 , wherein the daily dose is administered with food.

7. The method of claim 2 , further comprising administration of a second serum uric acid lowering agent.

8. The method of claim 7 , wherein the second serum uric acid lowering agent is a xanthine oxidase inhibitor.

9. The method of claim 8 , wherein the xanthine oxidase inhibitor is febuxostat or allopurinol.

10. The method of claim 3 , wherein the daily dose is administered orally.

11. The method of claim 3 , wherein the daily dose is administered in the morning.

12. The method of claim 3 , wherein the daily dose is administered with food.

13. The method of claim 3 , further comprising administration of a second serum uric acid lowering agent.

14. The method of claim 13 , wherein second serum uric acid lowering agent is febuxostat or allopurinol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2012
From: MINER, JEFFREY; GIRARDET, JEAN-LUC; QUART, BARRY D.
To: ARDEA BIOSCIENCES, INC.
Reel/Frame 029207/0765 →
Continuity (2)
Provisional Application 61319014 · Mar 30, 2010
Related Publication 20130059868A1 · Mar 7, 2013